Estimating the Share of Social Surplus Generated by Pharmaceutical Innovation Accruing to Manufacturers: A Systematic Literature Review
Applied Health Economics and Health Policy · 2026-11 · 24 (6) · 1029-1037
DOI: 10.1007/s40258-026-01064-0 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Applied Health Economics and Health Policy, online erschienen am 15.09.2026. Verfasst von Robert J Nordyke und 4 weiteren Autor:innen. Beteiligte Einrichtung: Beta6 Consulting, Topanga, United States. bob@beta6consulting.com. Hauptthemen laut MEDLINE: Drug Industry, Drug Development. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Pharmaceutical Council.
Abstract (Originalsprache)
Introduction
Pharmaceutical innovation operates within an implicit social contract that seeks to balance incentives for future drug development with equitable access to current therapies. A key metric for evaluating this balance is producer surplus (PS), which represents the share of total social surplus (the sum of consumer surplus [CS] and PS) captured by manufacturers. We explore the determinants and distribution of estimated supply-side surplus share across therapeutic areas, drug classes, and product life cycles.
Methods
We conducted a systematic literature review of empirical studies on PS in pharmaceuticals. Embase and EconLit databases were searched from database inception to April 2025. Search practices followed Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) guidance.
Results
A total of 24 studies were included, representing 68 unique PS estimates. Our analysis reveals wide variation in PS estimates, from 0.3% to 260%, with a median of approximately 15%. The range of estimates is driven primarily by disease-specific factors and methodological inconsistencies. Notably, most studies fail to account for the full spectrum of social benefits or to accurately identify manufacturer revenues, often conflating PS with broader supply chain gains. Only one study met rigorous criteria for both PS and CS definitions.
Conclusion
The limitations of current studies on PS hinder the utility of PS in value assessment and policymaking. We argue for greater methodological rigor and consistency to improve PS estimation and inform sustainable public policy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Beta6 Consulting, Topanga, United States. bob@beta6consulting.com.
- National Pharmaceutical Council, Washington, DC, USA.
- Petauri Evidence, York, England.
- Massachusetts College of Pharmacy and Health Sciences, Boston, MA, USA.
Förderung
- National Pharmaceutical Council
Zitieren
APA
Nordyke, R. J., Wagner, T. D., Ross, J., Menon, S., & Campbell, J. D. (2026). Estimating the Share of Social Surplus Generated by Pharmaceutical Innovation Accruing to Manufacturers: A Systematic Literature Review. Applied Health Economics and Health Policy, 24(6), 1029-1037. https://doi.org/10.1007/s40258-026-01064-0
Vancouver
Nordyke RJ, Wagner TD, Ross J, Menon S, Campbell JD. Estimating the Share of Social Surplus Generated by Pharmaceutical Innovation Accruing to Manufacturers: A Systematic Literature Review. Applied Health Economics and Health Policy. 2026;24(6):1029-1037. doi:10.1007/s40258-026-01064-0
BibTeX
@article{Nordyke2026,
author = {Nordyke, Robert J and Wagner, Tyler D and Ross, Janine and Menon, Sreeranjani and Campbell, Jonathan D},
title = {Estimating the Share of Social Surplus Generated by Pharmaceutical Innovation Accruing to Manufacturers: A Systematic Literature Review},
journal = {Applied Health Economics and Health Policy},
year = {2026},
volume = {24},
number = {6},
pages = {1029--1037},
doi = {10.1007/s40258-026-01064-0}
}
EUVIMED